tbuckley/cabot-search huggingface dataset:
Prognostic value of clinical complete response for patients with initially unresectable hepatocellular carcinoma after conversion with triple therapy
Authors: Jun-Yi Wu, Zhen-Xin Zeng, Yi-Nan Li, Zhi-Bo Zhang, Shao-Wu Zhuang, Bin Li, Jian-Yin Zhou, Shu-Qun Li, De-Yi Liu, Han Li, Xiang-Ye Ou, Jia-Yi Wu, Mao-Lin Yan
Journal: Liver Cancer (2025)

Introduction: Accurately predicting the outcomes of conversion therapy among patients with initially unresectable hepatocellular carcinoma (uHCC) remains a challenge. Clinical complete response (cCR) has been proposed as a predictor of prognosis. However, information on its prognostic value in these patients is limited. We aimed to explore the prognostic value of cCR in patients with uHCC following conversion therapy and identify predictors of cCR. Methods: We included 241 patients with uHCC who underwent transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors (triple therapy) as first-line treatment. The prognostic value of cCR, predictive factors of cCR, and the relationship between cCR and pathological complete response (pCR) were analyzed. Results: The cCR rate of the 241 patients included was 17.4%. Patients with cCR showed better overall survival (OS) (p &lt; 0.001) and progression-free survival (PFS) (p &lt; 0.001) than those without. cCR was an independent risk factor for OS (hazard ratio [HR]: 0.11, 95% confidence interval [CI]: 0.03–0.42, p = 0.001) and PFS (HR: 0.29, 95% CI: 0.15–0.56, p &lt; 0.001). Serum α-fetoprotein levels ≥400 ng/mL (odds ratio [OR]: 0.47, 95% CI: 0.22–0.95, p = 0.040) and extrahepatic metastasis (OR: 0.13, 95% CI: 0.01–0.62, p = 0.046) were independent negative predictors of cCR. A total of 107 patients (44.4%) underwent conversion surgery. Among these patients, cCR was associated with better OS (p =0.009) and recurrence-free survival (p = 0.007). cCR was significantly correlated with pCR (Φ = 0.61, p &lt; 0.001). Albumin levels ≥35 g/L (OR: 0.12, 95% CI: 0.02–0.69, p = 0.018) and cCR (OR: 30.32, 95% CI: 9.19–128.00, p &lt; 0.001) were independent predictors of pCR. Conclusion: cCR after triple therapy has an excellent long-term survival advantage and is significantly related to pCR. cCR may be a surrogate marker for predicting prognosis and pCR in patients with uHCC receiving triple therapy.
Non-invasive Kupffer-CEUS Enhances the Accuracy of FLLs Diagnosis in Patients with Liver Cirrhosis or Fibrosis: A prospective multicenter study from China
Authors: Yunlin Li, Xiao-Ling Yu, Xiang Jing, Hong Yang, Kaiyan Li, Wei Wu, Shichun Lu, Hong Ding, Guangjian Liu, Wen Cheng, Guangzhi He, Kai Li, Yan Luo, Liping Liu, Tianan Jiang, Guiming Zhou, Xiaoyan Xie, Zhigang Song, Fang-Yi Liu, Jie Yu, Zhi-Yu Han, Zhi-Gang Cheng, Shuilian Tan, Junqing Xi, Xuejuan Dong, Erpeng Qi, Jundong Yao, Xiaocong Dong, Ping Liang
Journal: Liver Cancer (2025)

Introduction: It is challenging to diagnose liver masses in the context of a rough liver background using CT and MRI. Perfluorobutane (PFB) CEUS microbubble, an ultrasound contrast agent, has a unique phase called the Kupffer phase. This study aimed to explore whether the diagnostic ability of Kupffer-CEUS is affected by the rough liver background. Methods: A prospective analysis was conducted on patients with access to histological pathology of FLLs and liver parenchyma from 23 centers between August 2020 and March 2021. Kupffer-CEUS was performed on 552 patients, who were divided into two groups (normal and abnormal) based on the pathological results of liver parenchyma, and the abnormal group was further divided into four groups (Sight liver fibrosis, Serious liver fibrosis, Fatty liver, Mixed). Kupffer-CEUS was divided into vascular phase and vascular &amp; Kupffer phase. Results: In Kupffer-CEUS, differences in diagnostic efficiency of FLLs between normal and abnormal liver backgrounds were not statistically significant. However, in patients with abnormal liver backgrounds, the specificity (57.45% vs. 74.47%, P=0.008) and accuracy (89.81% vs. 96.92%, P&lt;0.001) of the vascular phase in distinguishing malignant from benign lesions were statistically lower than those of the vascular &amp; Kupffer phase. Subgroup analysis revealed that the sensitivity, specificity, and accuracy of vascular &amp; Kupffer phase in screening FLLs were all higher than those of vascular phase, except for the accuracy in patients with serious liver fibrosis (98.51% vs. 94.06, P&lt;0.001). Conclusion: This study indicated that although there is no obvious restriction on the choice of Kupffer-CEUS methods when diagnosing liver masses in patients with normal or abnormal liver backgrounds, Kupffer phase CEUS can effectively reduce the misdiagnosis of FLLs. Particularly for patients with serious liver fibrosis, contrast-enhanced ultrasound combined with the Kupffer phase can provide a more accurate diagnosis than conventional contrast-enhanced ultrasonography.
Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial
Authors: Giulio Stefanini, Carmelo Carlo-Stella, Francesco Cannata, Mauro Chiarito, Stefano Figliozzi, Laura Novelli, Costanza Lisi, Sara Bombace, Federica Catapano, Eleonora Indolfi, Cristina Panico, Francesco Corrado, Giovanna Masci, Rita Mazza, Francesca Ricci, Lorenzo Monti, Giuseppe Ferrante, Bernhard Reimers, Armando Santoro, Marco Francone, Bruno R da Costa, Peter Jüni, Gianluigi Condorelli
Journal: Cardiovascular Research (2025)
Barriers To Cardiovascular Magnetic Resonance Imaging Scan Performance and Reporting by Cardiologists: A Systematic Literature Review
Authors: Tesfamariam Betemariam, Abeba Aleka, Ekram Ahmed, Tinsae Worku, Yonas Mebrahtu, Emmanuel Androulakis, Steffen E Petersen, Rocco Friebel
Journal:  (2025)

Cardiovascular magnetic resonance (CMR) imaging plays a pivotal role in diagnosing and managing cardiovascular diseases. Its use has shown sustained growth over the past years. However, there is considerable variability in the use and reporting of CMR scans worldwide. This review provides synthesis of evidence on the barriers and challenges to performing CMR scans by cardiologists and gain insights into the variations in CMR scan practices across different countries. We systematically reviewed the literature from 1 January 2003 up to 13 November 2023. We searched four databases (Ovid Medline, Embase, Web of Science, and Scopus) and hand-searched the references in the included articles, complemented by expert feedback. Articles were double screened against pre-defined inclusion and exclusion criteria. We conducted risk of bias using the JBI critical appraisal tool, and we analysed information using a narrative synthesis of results. We identified 14 857 articles, with 13 articles meeting the inclusion criteria. The key barriers were the limited availability of CMR scanners, resulting in extended waiting times, the high service cost, and limited training opportunities and the lack of a structured curriculum. The main practice variations identified were geographical disparities in CMR use. Worldwide, the majority of CMR training programmes are situated in radiology departments. Barriers to CMR use by cardiologists range from access to scanners and prohibitive costs to disparities in familiarity with CMR technology. Geographic variations and heterogeneity in training programmes underscore the influence of systemic factors such as healthcare infrastructure, reimbursement policies, and unstandardized training curricula.
PSC and colitis: A complex relationship
Authors: Ludwig J. Horst, Jan Kempski, Martine Walmsley, Samuel Huber, Christoph Schramm
Journal: Hepatology (2025)

Primary sclerosing cholangitis is one of the most challenging conditions in hepatology, and due to our limited understanding of its pathogenesis, no causal therapies are currently available. While it was long assumed that a minority of people with IBD also develop PSC, which is sometimes labeled an extraintestinal manifestation of IBD, the clinical phenotype, genetic and intestinal microbiota associations strongly argue for PSC-IBD being a distinct form of IBD, existing alongside ulcerative colitis and Crohn’s disease. In fact, the liver itself could contribute to intestinal pathology, clinically overt in 60 – 80 % of patients. Recent studies suggested that on a molecular level, almost all people with PSC have underlying colitis. The extent to which the liver and gut influence each other clinically and in terms of disease progression has not yet been conclusively revealed. However, while it seemed intuitive that the two diseases have a negative influence on each other, evidence suggests that sclerosing cholangitis can also be protective for the gut and that colitis can in certain settings ameliorate liver pathology. This underscores the complex pathophysiological relationships, where factors such as genetic predisposition, changes in the intestinal microbiota, altered bile acid metabolism, and immune cell migration are among the suspected contributors. PSC is an emerging disease with a significant impact on health-related quality of life of affected people. With this review, we aim to summarize the current knowledge on the gut-liver axis in PSC-IBD, provide new perspectives on risk stratification and treatment and identify gaps in our current knowledge. Our understanding of this complex relationship will therefore help to design clinical trials and shape the future therapy of PSC-IBD.
Dynamic co-evolution of transposable elements and the piRNA pathway in African cichlid fishes
Authors: Miguel Vasconcelos Almeida, Moritz Blumer, Chengwei Ulrika Yuan, Pío Sierra, Jonathan L. Price, Fu Xiang Quah, Aleksandr Friman, Alexandra Dallaire, Grégoire Vernaz, Audrey L. K. Putman, Alan M. Smith, Domino A. Joyce, Falk Butter, Astrid D. Haase, Richard Durbin, M. Emília Santos, Eric A. Miska
Journal: Genome biology (2025)

Abstract Background East African cichlid fishes have diversified in an explosive fashion, but the (epi)genetic basis of the phenotypic diversity of these fishes remains largely unknown. Although transposable elements (TEs) have been associated with phenotypic variation in cichlids, little is known about their transcriptional activity and epigenetic silencing. We set out to bridge this gap and to understand the interactions between TEs and their cichlid hosts. Results Here, we describe dynamic patterns of TE expression in African cichlid gonads and during early development. Orthology inference revealed strong conservation of TE silencing factors in cichlids, and an expansion of piwil1 genes in Lake Malawi cichlids, likely driven by PiggyBac TEs. The expanded piwil1 copies have signatures of positive selection and retain amino acid residues essential for catalytic activity. Furthermore, the gonads of African cichlids express a Piwi-interacting RNA (piRNA) pathway that targets TEs. We define the genomic sites of piRNA production in African cichlids and find divergence in closely related species, in line with fast evolution of piRNA-producing loci. Conclusions Our findings suggest dynamic co-evolution of TEs and host silencing pathways in the African cichlid radiations. We propose that this co-evolution has contributed to cichlid genomic diversity.
Understanding the Lymphatic System: Tissue-on-Chip Modeling
Authors: William J. Polacheck, J. Brandon Dixon, Wen Yih Aw
Journal: Annual Review of Biomedical Engineering (2025)

The lymphatic vasculature plays critical roles in maintaining fluid homeostasis, transporting lipid, and facilitating immune surveillance. A growing body of work has identified lymphatic dysfunction as contributing to the severity of myriad diseases and to systemic inflammation, as well as modulating drug responses. Here, we review efforts to reconstruct lymphatic vessels in vitro toward establishing humanized, functional models to advance understanding of lymphatic biology and pathophysiology. We first review lymphatic endothelial cell biology and the biophysical lymphatic microenvironment, with a focus on features that are unique to the lymphatics and that have been used as design parameters for lymphatic-on-chip devices. We then discuss the state of the art for recapitulating lymphatic function in vitro, and we acknowledge limitations and challenges to current approaches. Finally, we discuss opportunities and the need for further development of microphysiological lymphatic systems to bridge the gap in model systems between lymphatic cell culture and animal physiology.
MRI-based Modelling of Left Atrial Flow and Coagulation to Predict Risk of Thrombogenesis in Atrial Fibrillation
Authors: Ahmed Qureshi, Paolo Melidoro, Maximilian Balmus, Gregory Y H Lip, David A Nordsletten, Steven E Williams, Oleg Aslanidi, Adelaide de Vecchi
Journal: Medical Image Analysis (2025)

Atrial fibrillation (AF), impacting nearly 50 million individuals globally, is a major contributor to ischaemic strokes, predominantly originating from the left atrial appendage (LAA). Current clinical scores like CHA₂DS₂-VASc, while useful, provide limited insight into the pro-thrombotic mechanisms of Virchow's triad-blood stasis, endothelial damage, and hypercoagulability. This study leverages biophysical computational modelling to deepen our understanding of thrombogenesis in AF patients. Utilising high temporal resolution Cine magnetic resonance imaging (MRI), a 3D patient-specific modelling pipeline for simulating patient-specific flow in the left atrium was developed. This computational fluid dynamics (CFD) approach was coupled with reaction-diffusion-convection equations for key clotting proteins, leading to an innovative risk stratification score that combines clinical and modelling data. This approach categorises thrombogenic risk into low (A), moderate (B), and high (C) levels. Applied to a cohort of nine patients, pre- and post-catheter ablation therapy, this approach generates novel risk scores of thrombus formation, which are based of mechanistic characterisation of all aspects of the Virchow's triad. Currently, thrombogenesis mechanisms are not factored in widespread clinical risks scores based on demographic characteristics and co-morbidities. Notably, some patients with a CHA₂DS₂-VASc score of 0 (lowest clinical risk) exhibited much higher risks once the individual pathophysiology was accounted for. This discrepancy highlights the limitations of the CHA₂DS₂-VASc score in providing detailed mechanistic insights into patient-specific thrombogenic risk. This work introduces a comprehensive method for assessing thrombus formation risks in AF patients, emphasising the value of integrating biophysical modelling with clinical scores to enhance personalised stroke prevention strategies.
Molecular allergy diagnosis enabling personalized medicine.
Authors: Paolo Maria Matricardi, Marianne van Hage, Adnan Custovic, Peter Korosec, Alexandra F Santos, Rudolf Valenta
Journal: Journal of Allergy and Clinical Immunology (2025)

Allergic patients are characterized by complex and patient-specific IgE sensitization profiles to various allergens, which are accompanied by different phenotypes of allergic disease. Molecular allergy (MA) diagnosis establishes the patient's IgE reactivity profile at a molecular allergen level and has moved allergology into the "Precision Medicine" era. Molecular allergology started in the late 1980s with the isolation of the first allergen-encoding DNA sequences. Already in 2002, the first allergen microarrays were developed for the assessment of complex IgE sensitization patterns. Recombinant allergens are used for a precise definition of personal IgE reactivity profiles, identification of genuine IgE sensitization to allergen sources for refined prescription of allergen-specific immunotherapy and allergen avoidance diagnosis of co- versus cross-sensitization, epidemiological studies and prediction of symptoms, phenotypes, and development allergic disease. For example, molecular IgE sensitization patterns associated with more severe respiratory allergies, severe food allergy and allergy to honeybee or vespids are already established. The implementation of MA diagnosis into daily clinical practice requires continuous medical education, training of doctors in MA diagnosis and may be facilitated by clinical decision support systems such as diagnostic algorithms which may take advantage of artificial intelligence (AI).
Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation
Authors: Ioannis Zerdes, Panagiotis Filis, Georgios Fountoukidis, Ali Inan El-Naggar, Foteini Kalofonou, Antonio D’Alessio, Athanasios Pouptsis, Theodoros Foukakis, George Pentheroudakis, Johan Ahlgren, Daniel Smith, Antonios Valachis
Journal: JNCI Journal of the National Cancer Institute (2025)

Abstract Background Although precision oncology has rapidly been developed in recent years, its real-world impact and challenges in healthcare implementation remain underexplored. Through a meta-analysis of real-world evidence (RWE), we aimed at investigating the applicability and clinical impact of comprehensive cancer genome profiling (CGP) in cancer patients with metastatic solid tumors. Methods We systematically searched Medline, Embase, and Web of Science for RWE studies on CGP and matched therapies in metastatic solid tumors (publication period: 2012—2023). Pooled proportions of actionable genomic alterations, patients treated with matched targeted therapies, treatment, and survival outcomes were calculated. Data from Swedish cancer registries were used as a case-study for nationwide CGP implementation. Results Out of the 7218 identified studies, 144 were included in our analysis. 59.8% of CGP-tested patients had actionable genomic alterations, with 15.6% (95% Confidence Interval (CI) 13.4-18.2%) of them having received targeted therapy. Objective response was seen in 23.9% (95% CI 20.8-27.3%). Overall, CGP-guided treatment was correlated with prolonged progression-free survival (pooled Hazard Ratio (HR) = 0.63; 95% CI, 0.56-0.70; 18 studies) and overall survival (pooled HR = 0.60; 95% CI, 0.51-0.70; 21 studies) when compared to conventional treatment. Meta-regression time projections analyses showed that these rates will steadily increase by 2030. Conclusions Pooled analyses of RWE studies indicate that approximately one-fourth of the patients receiving CGP-matched treatment have an objective response. By utilizing meta-regression projections, our nationwide cancer registry case-study offers insights into the potential of precision oncology for patients with metastatic cancer and to inform future healthcare strategies.
The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM)
Authors: Maureen E Canavan, Sarah Westvold, Valerie Csik, Jeffrey Franks, Gabrielle Rocque, Cary P Gross, Kerin B Adelson
Journal: JNCI Journal of the National Cancer Institute (2025)

It has long been assumed that academic oncology practices are disadvantaged in value-based payment programs, due to patient complexity and research costs. This assumption not been tested. The Oncology Care Model (OCM) was a Medicare alternative payment model, which sought to curb costs while improving care. We assessed the impact of clinical trial (CT) participation on two outcomes: 1. cost and 2. practice performance among three participating NCI designated cancer centers using a random effects meta-analysis. The mean total Medicare cost per episode was $42,225 for CT episodes and $34,937 for non-CT episodes. Despite higher total costs, CT episodes were more likely to be under spending targets than non-CT episodes (odds ratio 0.37 (CI 0.25, 0.48). Drug costs in CT episodes were lower than in non-CT episodes, although this was only statistically significant at the largest volume practice. In conclusion, CTs may offer an advantage in value-based programs.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
Authors: Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre-Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean Marc Schiano de Colella, Mourad Tiab, Mohamad Mohty, Frédérique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hébraud, Laurent Flet, Jean-Valère Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cécile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Hélène Demarquette, Valentine Richez, Cherel Bruiec, Laurent Frenzel, Marie-Christiane MB Vekemans, Noemie Bigot, Hervé Avet-Loiseau, Jill Corre, Philippe Moreau
Journal: Blood (2025)
Comments on Consensus for Generalized Pustular Psoriasis
Authors: Shayan Waseh, Sylvia Hsu, Mark G. Lebwohl
Journal: JAMA Dermatology (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA
Authors: Ana Carolina Caballero Gonzalez, Cristina Ujaldón-Miró, Paula Pujol-Fernández, Rosanna Montserrat-Torres, Maria Guardiola-Perello, Eva Escudero-López, Irene Garcia-Cadenas, Albert Esquirol, Rodrigo Martino, Paola Jara-Bustamante, Pol Ezquerra Condeminas, Jose Manuel Soria, Eva Iranzo Ribera, Maria-Estela Moreno-Martinez, Mireia Riba, Jorge Sierra, Carmen Alvarez-Fernández, Laura Escribà-Garcia, Javier Briones
Journal: Blood (2025)
Bright Light Therapy for Nonseasonal Depressive Disorders
Authors: Hirofumi Hirakawa
Journal: JAMA Psychiatry (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal